MDxHealth SA ADR (EBR:MDXH), (NASDAQ:MDXH) specializes in providing actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company focuses on developing and marketing a range of novel genomic and epigenetic tests that assist physicians in the diagnosis and prognosis of cancer patients, as well as in predicting patients' response to certain treatments. Its flagship products are aimed at prostate, bladder, and kidney cancers, employing state-of-the-art genomics technologies to provide accurate and actionable insights. MDxHealth’s objective is to improve patient outcomes by leveraging molecular diagnostics that can lead to earlier detection and more personalized treatment approaches, ensuring better management of the disease. The company is dedicated to innovation in cancer care, continuously working on expanding its product portfolio and improving the precision of cancer diagnostics.